Next 10 |
home / stock / pmn:cc / pmn:cc news
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such ...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer&...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.(Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that compa...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases suc...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that the&...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil W...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced the selecti...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to Shareholder ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded prot...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer...
News, Short Squeeze, Breakout and More Instantly...
Promis Neurosciences Inc. Company Name:
PMN:CC Stock Symbol:
TSXC Market:
Promis Neurosciences Inc. Website:
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such ...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer&...
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.(Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer...